Evidence map›Paper›PMID 32348913›Full record

ArticleThe journal of allergy and clinical immunology. In practice2020

Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis.

Dubravka Smiljkovic, Renata Kiss, Christian Lupinek, Gregor Hoermann, Georg Greiner, Nadine Witzeneder, Gerhard Krajnik, Franz Trautinger, Susanne Vrtala, Irene Mittermann and 5 more

Open access · greenAbstract read
In one paragraph

Article in The journal of allergy and clinical immunology. In practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.International archives of allergy and immunology · 2022
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Dubravka SmiljkovicDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Renata KissDepartment of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria.
Christian LupinekDepartment of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria.
Gregor HoermannDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; Central Institute of Medical and Chemical Laboratory Diagnostics, University Hospital Innsbruck, Innsbruck, Austria.
Georg GreinerDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
Nadine WitzenederDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Gerhard KrajnikDepartment of Internal Medicine I, University Hospital St. Poelten, St. Poelten, Austria.
Franz TrautingerDepartment of Dermatology, University Hospital St. Poelten, St. Poelten, Austria.
Susanne VrtalaDepartment of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria.
Irene MittermannDepartment of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria.
Michael KundiInstitute of Environmental Health of the Medical University of Vienna, Vienna, Austria.
Bernd JilmaDepartment of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Rudolf ValentaDepartment of Pathophysiology and Allergy Research, Division of Immunopathology, Center for Pathophysiology, Immunology and Infectiology, Medical University of Vienna, Vienna, Austria; NRC Institute of Immunology FMBA of Russia, Moscow, Russia; Laboratory for Immunopathology, Department of Clinical Immunology and Allergy, Sechenov First Moscow State Medical University, Moscow, Russia; Karl Landsteiner University of Health Sciences, Krems, Austria.
Wolfgang R SperrDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: wolfgang.r.sperr@meduniwien.ac.at.
Peter ValentDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at.
Medical University of Vienna · ATSt. Pölten University of Applied Sciences · ATKarl Landsteiner University of Health Sciences · AT

Funding

Austrian Science Fund FWF F 4605Austrian Science Fund FWF F 4704Austrian Science Fund FWF P 26728Austrian Science Fund FWF P 32470
6 · The paper itself

Abstract

backgroundBecause of a high risk to develop fatal anaphylaxis, early detection of immunoglobulin E (IgE)-dependent allergy is of particular importance in patients with mastocytosis.

objectiveWe examined whether microarray-based screening for allergen-reactive IgE (allergen-chip) is a sensitive and robust approach to detect specific IgE in patients with mastocytosis.

methodsSera for 42 patients were analyzed, including 4 with cutaneous mastocytosis, 2 with mastocytosis in the skin, and 36 with systemic mastocytosis. In addition, sera from an age- and sex-matched control cohort (n = 42) were analyzed.

resultsIn 15 of 42 patients with mastocytosis (35.7%), specific IgE was detected by allergen-chip profiling. Ves v 5 and Bet v 1 were the most frequently detected allergens (Ves v 5: 16.7% of patients; Bet v 1: 11.9% of patients). Allergen reactivity was confirmed by demonstrating upregulation of CD203c on blood basophils upon exposure to the respective allergen(s) in these patients. Specific IgE was identified by chip studies in 11 of 26 patients with mastocytosis with mediator-related symptoms (42.3%) and in 4 of 14 patients with mastocytosis without symptoms (28.6%). In the cohort with known allergy, 9 of 9 patients (100%) had a positive allergen-chip result. In patients with mastocytosis without a known allergy (n = 31), the chip identified 6 positive cases (19.5%). The prevalence of chip-positive patients was slightly lower in the mastocytosis group (35.7%) compared with age- and sex-matched controls (40.5%).

conclusionsAlthough specific IgE may not be detectable in all sensitized patients with mastocytosis, allergy chip-profiling is a reliable screening approach for the identification of patients with mastocytosis suffering from IgE-dependent allergies.

Indexed as

AnaphylaxisMastocytosisAllergensBasophilsHumansImmunoglobulin EAllergensImmunoglobulin EAllergen-chipAllergyIgEMastocytosis

Identifiers

PMID32348913
PMCPMC7116130
OpenAlexW3019363813

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.